Half-Year 2022 Financial and Clinical Trials Update
Al submissions for existing products
Projects in phase II and III
RG6264
RG6396
Phesgo OBI
HER2+ BC
Gavreto
Tumor agnostic
RG7446
Tecentriq SC
2L NSCLC
New Molecular Entity (NME)
Additional Indication (AI)
Oncology/Hematology
Immunology
Infectious Diseases
Roche
Metabolism
Neuroscience
Ophthalmology
Other
Tecentriq + cabozantinib
RG7446
2L NSCLC
RG7446
Tecentriq + cabozantinib
RCC adv
Tecentriq + Avastin
RG7446
HCC adj
RG3502
Kadcyla + Tecentriq
2L+ HER-2+ PD-L1+ mBC
Kadcyla + Tecentriq
RG3502
HER-2+ eBC high-risk
Tecentriq + paclitaxel
RG7446
RG7446
Tecentriq²
NSCLC neoadj
RG7446
RG6413+
Ronapreve**
RG7446
RG6412
SARS-CoV-2 hospitalized (EU) ✓
Tecentriq
SCCHN adj
RG1594
Ocrevus SC
RMS & PPMS
Tecentriq
RG7446
TNBC adj
Tecentriq
High risk NMIBC
Tecentriq+ lurbinectedin
RG7446
ctDNA+ high-risk MIBC
1l maintenance SCLC
Actemra
Venclexta
RG1569
RG7601
RG3648
COVID-19 pneumonia¹✓
r/r MM t(11:14)
Xolair
food allergy
RG7601
Venclexta + azacitidine
1L MDS
RG7159
Tecentriq ± chemo
Tecentriq + capecitabine
RG7446
RG7446
or carbo/gem
RG6152
1L MUC
Xofluza
direct transmission
RG7159
Gazyva
lupus nephritis
RG7159
TNBC
Gazyva
Gazyva
systemic lupus
erythematosus
membranous nephropathy
Xofluza
RG7596
Polivy
1L DLBCL (US)
Alecensa
RG7853
RG6152
ALK+ NSCLC adj
influenza, pediatric
(0-1 year)
RG6168
Enspryng
myasthenia gravis
RG1594
Ocrevus higher dose
RMS & PPMS
2022
2023
2024
Status as of July 21, 2022
✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
1Approved in EU, filed in US
2filing timeline based on data from interim analysis
PDS-Port Delivery System with ranibizumab
OBI-On-Body Delivery System
**Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with
Regeneron Pharmaceuticals
2025 and beyond
77View entire presentation